Physician profile
Gary J Sheppard
NPI 1174502702
$10,288.12
in general payments reported to CMS, 2019-2025
38 companies · $1,159 in 2025
The $1,159 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,768 · 2020: $1,186 · 2021: $938 · 2022: $1,207 · 2023: $2,323 · 2024: $1,708 · 2025: $1,159.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,776 · Consulting Fee: $1,390 · Travel and Lodging: $23.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,775.83 |
| Consulting Fee | $1,390.00 |
| Travel and Lodging | $23.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $1,413.58 | 2023 | Vabysmo |
| Amgen INC. | $1,071.46 | 2019-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $941.78 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $829.31 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $647.13 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Sanofi-Aventis U.S. LLC | $467.11 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $416.56 | 2019-2025 | Jardiance |
| Pfizer INC. | $368.13 | 2019-2025 | |
| Glaxosmithkline, LLC. | $284.55 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Inspire Medical Systems, INC. | $276.99 | 2024 | Inspire |
| Merck Sharp & Dohme LLC | $255.07 | 2019-2025 | Capvaxive, Gardasil, Gardasil 9 |
| Genzyme Corporation | $254.88 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $232.12 | 2019-2025 | Austedo Xr |
| Astellas Pharma US INC | $230.70 | 2019-2022 | |
| Amarin Pharma, INC. | $224.50 | 2019-2023 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Sheppard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.